CRP and Joint swelling: The adverse events observed in three or more patients, in descending order of incidence, were joint pain (n = 7; 87.5%), increased C-reactive protein (CRP) levels (n = 5; 62.5%), treatment-related pain (n = 4; 50.0%), fever, and joint effusion (n = 3; 37.5% each).